Zynerba Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ZYNE)

$11.56 0.11 (0.96 %)
(As of 01/23/2018 06:21 AM ET)
Previous Close$11.45
Today's Range$11.40 - $11.78
52-Week Range$5.42 - $25.95
Volume269,000 shs
Average Volume342,100 shs
Market Capitalization$156.68 million
P/E Ratio-4.46
Dividend YieldN/A
BetaN/A

About Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals logoZynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

Receive ZYNE News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYNE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ZYNE
CUSIPN/A
Phone+1-484-5817505

Debt

Debt-to-Equity RatioN/A
Current Ratio8.65%
Quick Ratio8.65%

Price-To-Earnings

Trailing P/E Ratio-4.46332046332046
Forward P/E Ratio-4.64
P/E GrowthN/A

Sales & Book Value

Annual Sales$10,000.00
Price / Sales15,663.80
Cash FlowN/A
Price / CashN/A
Book Value$2.31 per share
Price / Book5.00

Profitability

Trailing EPS($2.59)
Net Income$-23,380,000.00
Net MarginsN/A
Return on Equity-50.64%
Return on Assets-45.05%

Miscellaneous

Employees12
Outstanding Shares13,550,000

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) posted its earnings results on Tuesday, November, 14th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.05. During the same quarter in the previous year, the firm earned ($0.67) earnings per share. View Zynerba Pharmaceuticals' Earnings History.

Where is Zynerba Pharmaceuticals' stock going? Where will Zynerba Pharmaceuticals' stock price be in 2018?

9 brokerages have issued twelve-month price objectives for Zynerba Pharmaceuticals' shares. Their forecasts range from $7.00 to $32.00. On average, they expect Zynerba Pharmaceuticals' share price to reach $15.50 in the next twelve months. View Analyst Ratings for Zynerba Pharmaceuticals.

What are Wall Street analysts saying about Zynerba Pharmaceuticals stock?

Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (12/8/2017)
  • 2. Cantor Fitzgerald analysts commented, "Encouraging, but Early. In our view, the effect sizes and statistical significant have been strongly encouraging for the small and exploratory Phase 2 study. Achieving 46% reduction (p<0.0001) across the primary endpoint of Anxiety, Depression, and Mood Scale (ADAMS), ZYN002 also has demonstrated clinically meaningful activity across domains of the disease as measured by Aberrant Behavior Checklist – FXS (ABC-FXS)."" (9/28/2017)
  • 3. Maxim Group analysts commented, "Zynerba announced the completion of target pediatric patient enrollment (n=16, ages from 6 – 17 years old) in the Phase II FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) study to evaluate ZYN002, Zynerba’s cannabidiol (CBD) gel in children with Fragile X syndrome (FXS)." (6/8/2017)

Who are some of Zynerba Pharmaceuticals' key competitors?

Who are Zynerba Pharmaceuticals' key executives?

Zynerba Pharmaceuticals' management team includes the folowing people:

  • Armando Anido, Chairman of the Board, Chief Executive Officer (Age 59)
  • Terri B. Sebree, President (Age 59)
  • James E. Fickenscher, Chief Financial Officer, Vice President - Corporate Development (Age 53)
  • Suzanne M. Hanlon, Secretary, General Counsel and Vice President, Human Resources (Age 60)
  • William Roberts, Vice President - Investor Relations and Corporate Communications
  • Ray Mannion, Vice President - Manufacturing
  • Brian Rosenberger, Vice President - Commercial (Age 48)
  • Liza Squires M.D., Chief Medical Officer
  • Warren D. Cooper M.D., Lead Independent Director (Age 64)
  • William J. Federici, Independent Director (Age 57)

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an initial public offering (IPO) on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

How do I buy Zynerba Pharmaceuticals stock?

Shares of Zynerba Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zynerba Pharmaceuticals' stock price today?

One share of Zynerba Pharmaceuticals stock can currently be purchased for approximately $11.56.

How big of a company is Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals has a market capitalization of $156.68 million and generates $10,000.00 in revenue each year. The company earns $-23,380,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Zynerba Pharmaceuticals employs 12 workers across the globe.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. Lancaster Avenue, Suite 300, DEVON, PA 19333, United States. The company can be reached via phone at +1-484-5817505 or via email at [email protected]


MarketBeat Community Rating for Zynerba Pharmaceuticals (ZYNE)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  241 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  388
MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.442.442.443.00
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $15.50$15.50$14.63$32.25
Price Target Upside: 15.16% upside13.14% upside65.82% upside82.51% upside

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Consensus Price Target History

Price Target History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/3/2018Cantor FitzgeraldSet Price TargetBuy$17.00HighView Rating Details
1/3/2018OppenheimerReiterated RatingHoldHighView Rating Details
12/4/2017Canaccord GenuitySet Price TargetOutperform -> Buy$15.00 -> $18.00HighView Rating Details
11/14/2017Piper Jaffray CompaniesBoost Price Target$16.00 -> $20.00N/AView Rating Details
10/1/2017Roth CapitalSet Price TargetBuy$15.00MediumView Rating Details
8/15/2017CIBCReiterated RatingOutperform -> Market PerformLowView Rating Details
8/15/2017HC WainwrightSet Price TargetHold$7.00LowView Rating Details
8/15/2017Jefferies GroupDowngradeBuy -> Hold$12.00 -> $7.00LowView Rating Details
8/14/2017Maxim GroupReiterated RatingHoldHighView Rating Details
(Data available from 1/23/2016 forward)

Earnings

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Earnings History and Estimates Chart

Earnings by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals (NASDAQ ZYNE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.59)($0.63)ViewN/AView Earnings Details
8/1/2017Q2 2017($0.60)($0.64)$0.38 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.55)($0.60)$0.07 millionViewN/AView Earnings Details
3/27/2017Q4 2016($0.75)($0.71)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.69)($0.67)$0.20 millionViewN/AView Earnings Details
8/11/2016Q2($0.53)($0.70)$0.03 millionViewN/AView Earnings Details
5/12/2016Q1($0.56)($0.49)$0.03 million$0.01 millionViewN/AView Earnings Details
3/14/2016Q415($0.29)($0.62)$0.20 million$0.05 millionViewN/AView Earnings Details
11/11/2015Q3($0.41)($0.44)$0.20 millionViewN/AView Earnings Details
8/27/2015Q2 2015($0.80)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.49 EPS
Next Year EPS Consensus Estimate: $-2.34 EPS

Dividends

Dividend History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Zynerba Pharmaceuticals (NASDAQ ZYNE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.91%
Institutional Ownership Percentage: 26.40%
Insider Trades by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Institutional Ownership by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals (NASDAQ ZYNE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2018Michael RappMajor ShareholderBuy15,000$12.99$194,850.00View SEC Filing  
10/23/2017Michael RappMajor ShareholderBuy25,745$9.94$255,905.30View SEC Filing  
10/19/2017Michael RappMajor ShareholderBuy44,255$9.59$424,405.45View SEC Filing  
5/15/2017Armando AnidoChairmanBuy5,000$19.70$98,500.00336,012View SEC Filing  
5/12/2017James E FickenscherCFOBuy5,200$19.82$103,064.0012,200View SEC Filing  
12/29/2016Michael RappMajor ShareholderBuy10,000$15.85$158,500.001,354,115View SEC Filing  
12/7/2016James E FickenscherCFOBuy7,000$14.08$98,560.003,000View SEC Filing  
8/16/2016Suzanne M HanlonInsiderSell3,000$10.53$31,590.0039,893View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Zynerba Pharmaceuticals (NASDAQ ZYNE) News Headlines

Source:
DateHeadline
Zynerba Pharmaceuticals Inc (ZYNE) Receives Consensus Rating of "Hold" from AnalystsZynerba Pharmaceuticals Inc (ZYNE) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 19 at 3:40 PM
Zacks: Analysts Anticipate Zynerba Pharmaceuticals Inc (ZYNE) to Post -$0.64 Earnings Per ShareZacks: Analysts Anticipate Zynerba Pharmaceuticals Inc (ZYNE) to Post -$0.64 Earnings Per Share
www.americanbankingnews.com - January 15 at 7:16 AM
BRIEF-Zynerba Pharmaceuticals Inc ‍Plans To Initiate Phase 2 Development Of ZYN001 In Tourette Syndrome By Year EndBRIEF-Zynerba Pharmaceuticals Inc ‍Plans To Initiate Phase 2 Development Of ZYN001 In Tourette Syndrome By Year End
www.reuters.com - January 4 at 4:22 PM
Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update - GlobeNewswire (press release)Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update - GlobeNewswire (press release)
globenewswire.com - January 4 at 10:34 AM
Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate UpdateZynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update
finance.yahoo.com - January 4 at 10:34 AM
Zynerba Pharmaceuticals Inc (ZYNE) Major Shareholder Purchases $194,850.00 in StockZynerba Pharmaceuticals Inc (ZYNE) Major Shareholder Purchases $194,850.00 in Stock
www.americanbankingnews.com - January 3 at 6:34 AM
-$0.64 Earnings Per Share Expected for Zynerba Pharmaceuticals Inc (ZYNE) This Quarter-$0.64 Earnings Per Share Expected for Zynerba Pharmaceuticals Inc (ZYNE) This Quarter
www.americanbankingnews.com - December 29 at 11:48 AM
Zynerba Pharmaceuticals Inc (ZYNE) Receives Consensus Recommendation of "Hold" from BrokeragesZynerba Pharmaceuticals Inc (ZYNE) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 25 at 1:52 PM
Zynerba Pharmaceuticals Inc (undefined:ZYNE): Does -3.8% EPS Drop In A Year Reflect The Long-Term Trend?Zynerba Pharmaceuticals Inc (undefined:ZYNE): Does -3.8% EPS Drop In A Year Reflect The Long-Term Trend?
finance.yahoo.com - December 13 at 4:29 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Expected to Announce Earnings of -$0.64 Per ShareZynerba Pharmaceuticals, Inc. (ZYNE) Expected to Announce Earnings of -$0.64 Per Share
www.americanbankingnews.com - December 12 at 8:48 AM
Legal Cannabis Sales Grow Globally - PR Newswire (press release)Legal Cannabis Sales Grow Globally - PR Newswire (press release)
www.prnewswire.com - December 11 at 11:19 AM
Zynerba Pharmaceuticals (ZYNE) Upgraded to "Hold" by Zacks Investment ResearchZynerba Pharmaceuticals (ZYNE) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - December 8 at 1:56 PM
Biotech Forum Daily Digest: Our Take On MiMedx - Seeking AlphaBiotech Forum Daily Digest: Our Take On MiMedx - Seeking Alpha
seekingalpha.com - December 5 at 4:17 PM
Zynerba Pharma (ZYNE) Positive ZYN002 Data from STAR 1 and ... - StreetInsider.comZynerba Pharma (ZYNE) Positive ZYN002 Data from STAR 1 and ... - StreetInsider.com
www.streetinsider.com - December 5 at 4:17 PM
Zynerba Pharmaceuticals Shares Volatile After Epilepsy Study Results - BenzingaZynerba Pharmaceuticals Shares Volatile After Epilepsy Study Results - Benzinga
www.benzinga.com - December 5 at 4:17 PM
Zynerba Pharmaceuticals Volatile After Epilepsy Study Results - BenzingaZynerba Pharmaceuticals Volatile After Epilepsy Study Results - Benzinga
www.benzinga.com - December 5 at 4:17 PM
Today’s Research Reports on Trending Tickers: Achillion Pharmaceuticals and Zynerba PharmaceuticalsToday’s Research Reports on Trending Tickers: Achillion Pharmaceuticals and Zynerba Pharmaceuticals
finance.yahoo.com - December 5 at 12:20 PM
Canaccord Genuity Analysts Give Zynerba Pharmaceuticals (ZYNE) a $18.00 Price TargetCanaccord Genuity Analysts Give Zynerba Pharmaceuticals (ZYNE) a $18.00 Price Target
www.americanbankingnews.com - December 4 at 7:32 PM
Zynerba Pharmaceuticals Volatile After Epilepsy Study ResultsZynerba Pharmaceuticals Volatile After Epilepsy Study Results
finance.yahoo.com - December 4 at 4:20 PM
Pre-Open Movers 12/04: (BGC) (EXAC) (ZYNE) Higher; (MZOR) (FNSR) (CVS) Lower (more...)Pre-Open Movers 12/04: (BGC) (EXAC) (ZYNE) Higher; (MZOR) (FNSR) (CVS) Lower (more...)
www.streetinsider.com - December 4 at 10:40 AM
Zynerba Pharmaceuticals (ZYNE) Given a $17.00 Price Target at Cantor FitzgeraldZynerba Pharmaceuticals (ZYNE) Given a $17.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - December 4 at 10:14 AM
Zynerba Pharmaceuticals, Inc. (ZYNE) Given Consensus Rating of "Hold" by BrokeragesZynerba Pharmaceuticals, Inc. (ZYNE) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 30 at 4:04 PM
 Brokerages Expect Zynerba Pharmaceuticals, Inc. (ZYNE) to Announce -$0.62 EPS Brokerages Expect Zynerba Pharmaceuticals, Inc. (ZYNE) to Announce -$0.62 EPS
www.americanbankingnews.com - November 24 at 11:16 AM
Cantor Fitzgerald Reiterates "$17.00" Price Target for Zynerba Pharmaceuticals, Inc. (ZYNE)Cantor Fitzgerald Reiterates "$17.00" Price Target for Zynerba Pharmaceuticals, Inc. (ZYNE)
www.americanbankingnews.com - November 21 at 8:15 PM
Is It The Right Time To Buy Zynerba Pharmaceuticals Inc (ZYNE)?Is It The Right Time To Buy Zynerba Pharmaceuticals Inc (ZYNE)?
finance.yahoo.com - November 20 at 9:32 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Receives Hold Rating from Oppenheimer Holdings, Inc.Zynerba Pharmaceuticals, Inc. (ZYNE) Receives Hold Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 19 at 10:20 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Downgraded by Zacks Investment Research to SellZynerba Pharmaceuticals, Inc. (ZYNE) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - November 18 at 9:44 AM
FY2017 EPS Estimates for Zynerba Pharmaceuticals, Inc. (ZYNE) Decreased by Oppenheimer HoldingsFY2017 EPS Estimates for Zynerba Pharmaceuticals, Inc. (ZYNE) Decreased by Oppenheimer Holdings
www.americanbankingnews.com - November 17 at 7:10 PM
Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights - GlobeNewswire (press release)Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights - GlobeNewswire (press release)
globenewswire.com - November 16 at 11:03 AM
Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational HighlightsZynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights
finance.yahoo.com - November 16 at 11:03 AM
Zynerba reports 3Q lossZynerba reports 3Q loss
finance.yahoo.com - November 16 at 11:03 AM
Piper Jaffray Companies Boosts Zynerba Pharmaceuticals, Inc. (ZYNE) Price Target to $20.00Piper Jaffray Companies Boosts Zynerba Pharmaceuticals, Inc. (ZYNE) Price Target to $20.00
www.americanbankingnews.com - November 15 at 12:16 AM
Analyzing Zynerba Pharmaceuticals (ZYNE) & BeyondSpring (BYSI)Analyzing Zynerba Pharmaceuticals (ZYNE) & BeyondSpring (BYSI)
www.americanbankingnews.com - November 14 at 7:40 AM
Critical Analysis: Zynerba Pharmaceuticals (ZYNE) & OncoSec Medical (ONCS)Critical Analysis: Zynerba Pharmaceuticals (ZYNE) & OncoSec Medical (ONCS)
www.americanbankingnews.com - November 11 at 3:28 PM
Biotech M&A Momentum Attractive for Cannabinoid R&D SpaceBiotech M&A Momentum Attractive for Cannabinoid R&D Space
www.prnewswire.com - November 7 at 4:23 PM
Zynerba Pharmaceuticals to Present at Upcoming Investor ConferencesZynerba Pharmaceuticals to Present at Upcoming Investor Conferences
finance.yahoo.com - November 7 at 4:23 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Given Consensus Recommendation of "Hold" by AnalystsZynerba Pharmaceuticals, Inc. (ZYNE) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 5 at 1:42 PM
Daily Technical Summary Reports on Generic Drugs Stocks -- Adamas Pharma, Neos Therapeutics, Zynerba Pharma ... - PR Newswire (press release)Daily Technical Summary Reports on Generic Drugs Stocks -- Adamas Pharma, Neos Therapeutics, Zynerba Pharma ... - PR Newswire (press release)
www.prnewswire.com - October 30 at 8:53 AM
Zynerba Pharmaceuticals, Inc. (ZYNE) Sees Large Increase in Short InterestZynerba Pharmaceuticals, Inc. (ZYNE) Sees Large Increase in Short Interest
www.americanbankingnews.com - October 28 at 2:26 AM
How Biosynthesis is Revolutionizing Cannabinoid PharmaceuticalsHow Biosynthesis is Revolutionizing Cannabinoid Pharmaceuticals
www.marketwatch.com - October 24 at 12:56 PM
3 Marijuana Stocks That Like to Live Life Dangerously3 Marijuana Stocks That Like to Live Life Dangerously
finance.yahoo.com - October 24 at 12:56 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Major Shareholder Michael Rapp Buys 25,745 SharesZynerba Pharmaceuticals, Inc. (ZYNE) Major Shareholder Michael Rapp Buys 25,745 Shares
www.americanbankingnews.com - October 23 at 10:34 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Major Shareholder Buys $424,405.45 in StockZynerba Pharmaceuticals, Inc. (ZYNE) Major Shareholder Buys $424,405.45 in Stock
www.americanbankingnews.com - October 23 at 10:34 PM
Critical Analysis: Zynerba Pharmaceuticals (ZYNE) and Alnylam Pharmaceuticals (ALNY)Critical Analysis: Zynerba Pharmaceuticals (ZYNE) and Alnylam Pharmaceuticals (ALNY)
www.americanbankingnews.com - October 22 at 10:10 AM
Zynerba Pharmaceuticals, Inc. (ZYNE) Rating Lowered to Hold at Zacks Investment ResearchZynerba Pharmaceuticals, Inc. (ZYNE) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 18 at 8:58 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Upgraded to "Buy" at Zacks Investment ResearchZynerba Pharmaceuticals, Inc. (ZYNE) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - October 14 at 5:16 PM
Like a Weed, This Marijuana Stock Catapulted Higher by 34% Last WeekLike a Weed, This Marijuana Stock Catapulted Higher by 34% Last Week
finance.yahoo.com - October 12 at 10:37 AM
Zynerba Pharmaceuticals, Inc. (ZYNE) Receives Average Rating of "Hold" from AnalystsZynerba Pharmaceuticals, Inc. (ZYNE) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - October 11 at 4:42 PM
Benzingas Top Upgrades, Downgrades For October 2, 2017 - BenzingaBenzinga's Top Upgrades, Downgrades For October 2, 2017 - Benzinga
www.benzinga.com - October 3 at 4:42 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Given a $15.00 Price Target by Roth Capital AnalystsZynerba Pharmaceuticals, Inc. (ZYNE) Given a $15.00 Price Target by Roth Capital Analysts
www.americanbankingnews.com - October 2 at 3:14 PM

SEC Filings

Zynerba Pharmaceuticals (NASDAQ:ZYNE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Zynerba Pharmaceuticals (NASDAQ ZYNE) Stock Chart for Tuesday, January, 23, 2018

Loading chart…

This page was last updated on 1/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.